Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced three new members of its leadership team: Mark Barrett joins Madrigal as Chief Business Officer, Clint Wallace joins as Chief Human Resources Officer and Tina Ventura joins as Chief Investor Relations Officer.
Related news for (MDGL)
- Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
- Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
- Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
- Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra